Beta Bionics announced it expects to fully commercialize its Mint patch pump by the end of Q2 2027, subject to FDA regulatory clearance, based on positive FDA responses and manufacturing scaling progress. The product aims to expand insulin pump options for diabetes patients by offering a smaller form factor compatible with the company's proprietary adaptive dosing algorithm.